US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition

Published April 30, 2024 10:03 AM

By MATTHEW PERRONE
AP Health Writer

WASHINGTON (AP) — The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic. Tuesday’s announcement is part of a wider effort by the Biden administration targeting pharmaceutical industry practices that contribute to high prices. The agency is taking issue with patents on popular drugs for weight loss, diabetes, asthma and other respiratory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and other companies are inaccurate or illegitimate. Drugmakers routinely use patents to protect new drugs and fight off competition from lower-priced generics.

Article Topic Follows: AP-National

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KION 46 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.